Imatinib: In Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By Cross Sarah A.   Lyseng-Williamson Katherine A.  

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2645-2654

Adis International

Access to resources Recommend Favorite

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By Soverini Simona   De Benedittis Caterina   Papayannidis Cristina   Paolini Stefania   Venturi Claudia   Iacobucci Ilaria   Luppi Mario   Bresciani Paola   Salvucci Marzia   Russo Domenico   Sica Simona   Orlandi Ester   Intermesoli Tamara   Gozzini Antonella   Bonifacio Massimiliano   Rigolin Gian Matteo   Pane Fabrizio   Baccarani Michele   Cavo Michele   Martinelli Giovanni  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

Blackwell Publishing

Access to resources Recommend Favorite

Enhancement of Imatinib-Induced Apoptosis by Matrine in bcr/abl-Positive Leukemia K562 Cells

By Liu Xiao-Shan   Jiang JiKai  

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 44, Iss. 4, 2006-06 ,pp. : 287-291

Informa Healthcare

Access to resources Recommend Favorite

Vincristine and dexamethasone pulses do not enhance intensive chemotherapy for patients with intermediate-risk acute lymphoblastic leukaemia

By  

Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

By Doggrell Sheila A   Christensen Anne-Marie  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 157-163

Informa Healthcare

Access to resources Recommend Favorite